Literature DB >> 11160674

Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir.

R T Sarisky1, M R Quail, P E Clark, T T Nguyen, W S Halsey, R J Wittrock, J O'Leary Bartus, M M Van Horn, G M Sathe, S Van Horn, M D Kelly, T H Bacon, J J Leary.   

Abstract

Penciclovir (PCV), an antiherpesvirus agent in the same class as acyclovir (ACV), is phosphorylated in herpes simplex virus (HSV)-infected cells by the viral thymidine kinase (TK). Resistance to ACV has been mapped to mutations within either the TK or the DNA polymerase gene. An identical activation pathway, the similarity in mode of action, and the invariant cross-resistance of TK-negative mutants argue that the mechanisms of resistance to PCV and ACV are likely to be analogous. A total of 48 HSV type 1 (HSV-1) and HSV-2 isolates were selected after passage in the presence of increasing concentrations of PCV or ACV in MRC-5 cells. Phenotypic analysis suggested these isolates were deficient in TK activity. Moreover, sequencing of the TK genes from ACV-selected mutants identified two homopolymeric G-C nucleotide stretches as putative hot spots, thereby confirming previous reports examining Acv(r) clinical isolates. Surprisingly, mutations identified in PCV-selected mutants were generally not in these regions but distributed throughout the TK gene and at similar frequencies of occurrence within A-T or G-C nucleotides, regardless of virus type. Furthermore, HSV-1 isolates selected in the presence of ACV commonly included frameshift mutations, while PCV-selected HSV-1 mutants contained mostly nonconservative amino acid changes. Data from this panel of laboratory isolates show that Pcv(r) mutants share cross-resistance and only limited sequence similarity with HSV mutants identified following ACV selection. Subtle differences between PCV and ACV in the interaction with viral TK or polymerase may account for the different spectra of genotypes observed for the two sets of mutants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160674      PMCID: PMC114085          DOI: 10.1128/JVI.75.4.1761-1769.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  MUTANT STRAINS OF HERPES SIMPLEX DEFICIENT IN THYMIDINE KINASE-INDUCING ACTIVITY.

Authors:  D R DUBBS; S KIT
Journal:  Virology       Date:  1964-04       Impact factor: 3.616

2.  Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.

Authors:  C Pichoud; B Seignères; Z Wang; C Trépo; F Zoulim
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

3.  Evidence for control of herpes simplex virus mutagenesis by the viral DNA polymerase.

Authors:  J D Hall; R E Almy
Journal:  Virology       Date:  1982-01-30       Impact factor: 3.616

4.  Thymidine plaque autoradiography of thymidine kinase-positive and thymidine kinase-negative herpesviruses.

Authors:  R B Tenser; J C Jones; S J Ressel; F A Fralish
Journal:  J Clin Microbiol       Date:  1983-01       Impact factor: 5.948

5.  Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants.

Authors:  E Pelosi; G B Mulamba; D M Coen
Journal:  Antiviral Res       Date:  1998-01       Impact factor: 5.970

6.  Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants.

Authors:  M Ida; S Kageyama; H Sato; T Kamiyama; J Yamamura; M Kurokawa; M Morohashi; K Shiraki
Journal:  Antiviral Res       Date:  1999-01       Impact factor: 5.970

7.  Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance.

Authors:  G Darby; H J Field; S A Salisbury
Journal:  Nature       Date:  1981-01-01       Impact factor: 49.962

8.  Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates.

Authors:  D S Parris; J E Harrington
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

9.  Differential phosphorylation of (E)-5-(2-bromovinyl)-2'-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus.

Authors:  J A Fyfe
Journal:  Mol Pharmacol       Date:  1982-03       Impact factor: 4.436

10.  Survey of resistance of herpes simplex virus to acyclovir in northwest England.

Authors:  J Christophers; J Clayton; J Craske; R Ward; P Collins; M Trowbridge; G Darby
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

View more
  19 in total

Review 1.  Slipping and sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug-resistance.

Authors:  Anthony Griffiths
Journal:  Drug Resist Updat       Date:  2011-09-22       Impact factor: 18.500

Review 2.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin.

Authors:  Graciela Andrei; Jan Balzarini; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.

Authors:  Sonia Burrel; Claire Deback; Henri Agut; David Boutolleau
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

5.  Differential mutation patterns in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir or penciclovir.

Authors:  Tatsuo Suzutani; Ken Ishioka; Erik De Clercq; Kei Ishibashi; Hisatoshi Kaneko; Toshihiko Kira; Koh-Ichi Hashimoto; Masahiro Ogasawara; Katsuki Ohtani; Nobutaka Wakamiya; Masayuki Saijo
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

6.  In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs.

Authors:  G Andrei; D Topalis; P Fiten; C McGuigan; J Balzarini; G Opdenakker; R Snoeck
Journal:  J Virol       Date:  2011-12-21       Impact factor: 5.103

7.  Translational compensation of a frameshift mutation affecting herpes simplex virus thymidine kinase is sufficient to permit reactivation from latency.

Authors:  Anthony Griffiths; Shun-Hua Chen; Brian C Horsburgh; Donald M Coen
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

8.  Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines.

Authors:  Jeffry J Leary; Robert Wittrock; Robert T Sarisky; Adriana Weinberg; Myron J Levin
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

Review 9.  A review of antiviral drugs and other compounds with activity against feline herpesvirus type 1.

Authors:  Sara M Thomasy; David J Maggs
Journal:  Vet Ophthalmol       Date:  2016-04-19       Impact factor: 1.644

10.  Penciclovir susceptibilities of herpes simplex virus isolates from patients using penciclovir cream for treatment of recurrent herpes labialis.

Authors:  Robert T Sarisky; Teresa Bacon; Ron Boon; Leslie Locke; Tammy T Nguyen; Jeffry Leary; Klaus Esser; Robin Saltzman
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.